Global Market and Political Roundup: Eli Lilly Oncology Data, China Fiscal Growth, and Geopolitical Tensions
Key Takeaways Eli Lilly (LLY) reported a 79% confirmed objective response rate for its next-generation ADC in platinum-sensitive ovarian cancer, […]
